Hybridize Therapeutics

Private

OegstgeestHealthcare & Life Scienceshttps://hybridizetherapeutics.com/

Last Round

Strategic

Feb 9, 2022

Total Funding Raised

$315,000

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Hybridize Therapeutics is a biotechnology company developing kidney-targeted RNA-based therapies for patients with acute and chronic kidney diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

antisense oligonucleotideASORNA therapykidney disease therapyantisense therapyBK virus therapydrug licensingkidney transplant therapyoligonucleotide therapydirect-acting antiviralnephrology therapeuticspolyomavirus therapyintracellular antiviralanti-fibrotic therapygene silencing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Hybridize Therapeutics Comparables

Compare Hybridize Therapeutics with similar companies based on industry and business-model similarity.

Hybridize Therapeutics comparables — related companies by embedding similarity
Company	Similarity	Market Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Hybridize Therapeutics Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Strategic	Feb 9, 2022
Accelerator	Jun 29, 2018

View all Funding Rounds

Hybridize Therapeutics Investors

Notable investors and investment history

Hybridize Therapeutics investors
Investor	Rounds
Mibiton Foundation	Debt
Netherlands Organization for Scientific Research	Debt
Life Sciences @ Work Venture Challenge	Accelerator

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Apr 23, 2026
Monthly visitors grew 124% MoM, reaching 1.3K.
Jan 20, 2026
Monthly visitors grew 41% MoM.

View all signals

Hybridize Therapeutics Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Hybridize Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Hybridize Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersOegstgeest

Employee Range2

Year Founded2019

Last FundingFeb 9, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.